SGLT2 inhibitor (early-stage)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SGLT2 inhibitor (early-stage), covering 2026-06-25 to 2026-06-25. Get the full timeline:
Most recent: Clinical Trial Results: Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease